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Trivalent native outer membrane vesicles (nOMVs) derived from three genetically modified Neisseria
meningitidis serogroup B strains have been previously evaluated immunologically in mice and rabbits.
This nOMV vaccine elicited serum bactericidal activity (SBA) against multiple N. meningitidis serogroup
B strains as well as strains from serogroups C, Y, W, and X. In this study, we used trivalent nOMVs isolated
from the same vaccine strains and evaluated their immunogenicity in an infant Rhesus macaque (IRM)
model whose immune responses to the vaccine are likely to be more predictive of the responses in
human infants. IRMs were immunized with trivalent nOMV vaccines and sera were evaluated for exoge-
nous human serum complement-dependent SBA (hSBA). Antibody responses to selected hSBA generating
antigens contained within the trivalent nOMVs were also measured and we found that antibody titers
against factor H binding protein variant 2 (fHbpv2) were very low in the sera from animals immunized
with these original nOMV vaccines. To increase the fHbp content in the nOMVs, the vaccine strains were
further genetically altered by addition of another fHbp gene copy into the porB locus. Trivalent nOMVs
from the three new vaccine strains had higher fHbp antigen levels and generated higher anti-fHbp anti-
body responses in immunized mice and IRMs. As expected, fHbp insertion into the porB locus resulted in
no PorB expression. Interestingly, higher expression of PorA, an hSBA generating antigen, was observed
for all three modified vaccine strains. Compared to the trivalent nOMVs from the original strains, higher
PorA levels in the improved nOMVs resulted in higher anti-PorA antibody responses in mice and IRMs. In
addition, hSBA titers against other strains with PorA as the only hSBA antigen in common with the vac-
cine strains also increased.
 2016 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ. Published by
Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Neisseria meningitidis is a Gram-negative diplococcus and an
obligate human pathogen. Meningococcal strains can be divided
into multiple serogroups based on chemically and antigenically
distinct polysaccharide capsule expression. Six capsular polysac-
charide serogroups of N. meningitidis (A, B, C, W, X, and Y) cause
nearly all cases of invasive meningococcal disease [1]. These infec-
tions have different clinical consequences including meningitis and
septicemia. For serogroups A, C, Y and W, capsular polysaccharide
vaccines (such as Menomune [2]) and capsular polysaccharide
conjugate vaccines (such as Menactra [3]) have been licensed,
based on the induction of a functional antibody response only(serum bactericidal activity, SBA) [4]. A polysaccharide approach
is not being pursued for serogroup B (MenB) due to poor immuno-
genicity and potential cross-reactivity between the MenB polysac-
charide capsule and human tissue antigens [5–7]. Vaccine
development efforts for MenB have therefore focused on non-
capsular polysaccharide immunogens, particularly outer mem-
brane proteins either in the form of purified recombinant proteins
or outer membrane vesicles (OMVs) which are prepared from outer
membrane ‘‘blebs” spontaneously produced by the bacteria.
Recently, two recombinant protein containing MenB vaccines, Bex-
sero and Trumenba, have been approved [8,9].
The meningococcus has an outer membrane which contains
numerous protein types. Some of these proteins are used for fur-
ther classification of meningococci into serotypes and serosub-
types, based on antigenic differences in their major outer
membrane proteins, PorB and PorA, respectively [10,11]. The
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L. Zhang et al. / Vaccine 34 (2016) 4250–4256 4251lipo-oligosaccharide (LOS), embedded in the outer membrane,
determines 12 different immunotypes [10,12]. OMV-based vacci-
nes have the advantage of including several outer-membrane pro-
teins in properly folded conformations which might help to elicit
a protective immunological response. OMVs may be prepared by
known methods comprising a detergent extraction of the bacte-
rial cells, which has the benefit of reducing LOS endotoxin and
most of the capsular polysaccharide from the vaccine. However,
detergent extraction also reduces or eliminates conserved protec-
tive lipoproteins such as factor H binding protein (fHbp) [13]. In
children under two years of age, OMV vaccines produced from
detergent extraction generate a predominately PorA-specific
SBA response and will thus only protect against strains with the
same PorA serosubtype [14]. Therefore, vaccines based on
extracted OMVs from epidemic outbreak MenB strains were used
with success to control local clonal outbreaks [15–18] but did not
offer broad protection against heterologous strains with different
PorA subtypes. This lack of broad protection restricts the ability of
these OMVs to be used as a universal MenB vaccine.
Alternatively, native OMV (nOMV) have been purified from
meningococci without detergent extraction [19–21]. These
vesicles are not depleted of LOS or lipoproteins and the outer
membrane proteins are likely to be present in their native
conformation. Zollinger et al. designed a genetically engineered
trivalent nOMV vaccine from three parent strains H44/76, 8570
and B16B6 [21] (Table 1). The vaccine was designed to include
multiple outer membrane antigens such as PorA, fHbp, NadA,
Opc and LOS, each with the capability to induce SBA. The trivalent
nOMV vaccine was immunogenic in mice and rabbits, and elicited
functional SBA antibody responses against strains from not only
MenB, but also other serogroups, due to conserved cross-
reactive antigens [21–23]. A small phase I study in healthy adults
with a monovalent nOMV vaccine (from strain B2) was also
conducted and the vaccine was shown to be safe and immuno-
genic [24]. However, the trivalent nOMV vaccine has not been
tested in either humans or non-human primates.
To enhance safety of the trivalent nOMV vaccine, the lpxL1 gene
was deleted from the vaccine strains, resulting in mutant LOSwith
penta-acylated lipid A which has attenuated endotoxin activity
[21]. Previous studies have shown that mouse dendritic cells were
stimulated by the penta-acylated LOS, and the cytokine responses
might result in a potent adjuvant effect [25], where human den-
dritic cells showed marked decreased responses to penta-
acylated LOS [26]. The adjuvant effect of penta-acylated LOS in
immunized non-human primates were much lower and likely to
be similar to that in humans, suggesting that a non-human pri-
mate model might be more suitable to predict the antibody
responses to these modified nOMV vaccines in humans [27].
Because human infants are the primary target for a MenB vaccine,
we sought to evaluate the immunogenicity of this trivalent nOMVs
vaccine in an infant non-human primate model. Infant Rhesus
macaques (IRMs) were immunized with trivalent nOMV vaccines
and sera were evaluated for hSBA and antigen-specific antibody
responses. We found that antibody responses against fHbp variant
2 (fHbpv2) were very low, even though the vaccine strain B3 was
genetically engineered to increase its expression level [21]. There-
fore, we further genetically modified the vaccine strains by adding
another fHbp gene copy into the porB locus of each vaccine strain
to increase the fHbp content in all the three nOMVs. We showed
here that genetic modification can further improve the immuno-
genicity and breadth of the nOMV MenB vaccines.
2. Material and methods
Details on material and methods can be found in Supplemental
material section.
Table 2
Serum bactericidal antibody titers induced by the original trivalent nOMV vaccines in infant Rhesus macaques.
Study
group
Number of
animals
Immunogen Test strain
44/76 8570 B16B6
hSBA geomean
titers
Sero-
conversion (%)a
hSBA geomean
titers
Sero-
conversion (%)a
hSBA geomean
titers
Sero-
conversion (%)a
Group 1 9 Trivalent nOMV/AlPO4 13 100 27 100 348 100
Group 2 9 Trivalent nOMV/AlOH 14 89 20 100 174 100
Group 3 9 Trivalent nOMV/no
adjuvant
5 44 3 44 51 100
a Sero-conversion = >4 fold rise in hSBA titer for post vs. pre immunization sera.
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Fig. 1. IgG antibody responses in infant Rhesus macaques vaccinated with trivalent
nOMV vaccines derived from the original vaccine strains. Geomean ED50 (effective
dilution that achieves 50% fluorescence signal) ELISA titers were shown in log scale
against individual vaccine antigens. Error bar represents standard deviation.
4252 L. Zhang et al. / Vaccine 34 (2016) 4250–42563. Results
3.1. Immunogenicity of a trivalent nOMV vaccine in IRMs
We intramuscularly immunized three groups of IRMs
(2–4 months of age at the start of the study) with the prepared
trivalent nOMV vaccines on weeks 0, 8 and 16. Groups of IRMs
were given nOMV vaccines without adjuvant or with an aluminum
adjuvant, at a dose of 37.5 lg of total nOMV proteins. Serum was
collected on week 20 and evaluated in hSBA and antigen-specific
ELISA assays. The trivalent nOMV vaccines were immunogenic in
IRMs and elicited hSBA (Table 2). We showed that with an
aluminum phosphate adjuvant (AlPO4), IRMs were 100% sero-
converted against all three vaccine parent strains. Animals
receiving nOMV vaccines with aluminum hydroxide adjuvant
(AlOH) were 100% sero-converted against two of the parent strains,
and only one out of nine animals did not generate hSBA antibody
against the 44/76 strain. nOMVs without adjuvant elicited lower
immune response, as expected. In the phase I clinic trial, the mono-
valent nOMV vaccine formulated with AlOH adjuvant was shown
to be safe in healthy adults [24]. Our IRM data suggested that an
adjuvant such as an aluminum adjuvant might be necessary for
use with this vaccine in infants.
We next evaluated antibody responses against individual vac-
cine antigens including PorAs, NadA, fHbpv1 and fHbpv2, as those
antigens were either added or designed to be over-expressed in the
vaccine strains. We observed significant serum antibody titers in
immunized animals (group 1, nOMV with AlPO4) against all sixPorAs, as well as NadA and fHbpv1 (Fig. 1), suggesting that these
antigens are presented in the nOMV vaccines at immunogenic
levels. Using a quantitative mass spectrometry (QMS) method
[28], we determined that nOMV from strain B2 consists of
0.53% of fHbpv1 antigen while nOMVs from strain B3 consists
of only 0.13% of fHbpv2 antigen (Fig. 2B). Consistently, the anti-
body response against fHbpv2 in the immunized IRM sera was
much lower compared to the response to fHbpv1 (Fig. 1). The lower
antibody responses against fHbpv2 might also result from
sequence differences between the two fHbp types. Zollinger et al.
reported increased anti-NadA and anti-fHbpv1 antibody titers in
mice immunized with genetically engineered nOMVs, compared
to the unmodified strains, however, they did not report increased
anti-fHbpv2 antibody responses in mice [21]. A previous study
suggested that a critical threshold of fHbp expression is required
in broad protective antibody responses elicited by nOMV vaccines
[29], therefore, we sought to further genetically modify the vaccine
strains to increase the expression level of fHbpv2.
3.2. Genetic modification and verification
PorB protein is the most abundant protein on the surface of all
three nOMVs (Fig. 2C, for strain B3; data not shown for strains B1
and B2). Although PorB does induce SBA antibodies in an SBA assay
using baby rabbit serum as the source of exogenous complement
[30], it appears to be less immunogenic, especially in the infant
population [14,31,32]. Therefore, it might be dispensable in the
vaccine strains. We chose to introduce an fHbpv2 gene (fHbpv2.16)
into the porB locus of both strain B1 and strain B3 by homologous
recombination. As fHbpv1 has been shown to be an important vac-
cine antigen and is included in both of the licensed MenB vaccines,
Bexsero and Trumenba, we also introduced an fHbpv1 gene
(fHbpv1.1) similarly into the porB locus of strain B2 to further
increase its expression level. The final genetically modified vaccine
strains are designated as NB1, NB2 and NB3 (Table 1). These
improved vaccine strains grow well in cell culture medium, sug-
gesting the porB gene is not required for fitness of the bacteria
in vitro and these strains are suitable to use for vaccine
manufacture.
We evaluated surface expression of the antigens in these
improved vaccine strains using a whole cell flow cytometry anti-
body binding assay (Fig. 2A). As expected, we detected no surface
expression of PorB in the improved NB3 strain, as opposed to the
original B3 strain. We also obtained much higher levels of fHbpv2
for the improved NB3 strain, compared to the original strain. These
data verified the genetic modification we performed and results for
the NB1 and NB2 strains were similar (data not shown). We next
purified and characterized nOMVs derived from these improved
vaccine strains, and measured fHbp levels in the purified nOMVs
using QMS [28]. Consistent with our whole bacteria antibody bind-
ing data, the improved nOMVs indeed consist of much higher
levels of fHbp antigens (Fig. 2B), suggesting that exogenous genes
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Fig. 2. Increased levels of fHbp and PorA antigens in the improved vaccine strains. (A) Surface expression of vaccine antigens in the original B3 strain (black bars) vs. the
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Fig. 3. IgG antibody responses in mice (10 per group) vaccinated with monovalent
nOMV vaccines derived from the original or improved vaccine strains. Geomean
ED50 ELISA titers were shown in log scale against vaccine antigens whose levels
were increased in each of the three improved vaccine strains. Black bars represent
titers from the original vaccine strains while gray bars represent titers from the
improved vaccine strains. Error bar represents standard deviation.
L. Zhang et al. / Vaccine 34 (2016) 4250–4256 4253are expressed to a high level from the porB locus. On a SDS–PAGE
gel (Fig. 2C), nOMV from the NB3 strain clearly shows the absence
of the PorB band, as compared to the nOMV from the originalstrain. Interestingly, it appeared that the amount of PorA antigen
was increased in the NB3 strain. To verify this finding, we per-
formed whole cell flow cytometry antibody binding experiments
on strains B3 and NB3 using antibodies against PorAs and indeed
observed higher surface expression levels of both native (nPorA)
and recombinant (rPorA) PorAs (Fig. 2A). Similarly, NB1 and NB2
strains also contain increased levels of PorA expression (data not
shown).3.3. Immunogenicity of the improved trivalent nOMV vaccine in
animals
nOMVs from the original vaccine strains or the improved strains
were formulated with AAHS and evaluated individually as mono-
valent vaccines in CD-1 mice. Immunized mouse sera were tested
in ELISA assays for antigen specific antibody responses (Fig. 3).
Overexpression of fHbpv2 in the porB locus resulted in at least
2–3 logs higher antigen-specific antibody titers in mice immunized
with either NB1 or NB3 nOMV vaccine. nOMV from the original
strain B2, with an fHbpv1 level of 0.53% of total nOMV protein,
already induced high anti-fHbpv1 antibody titers. However, we
showed that overexpression of fHbpv1 in the porB locus further
increased the antibody response about 3 fold higher. Although
the amount of fHbpv1 and fHbpv2 are similar in the improved
strains as measured by QMS, fHbpv1 was able to elicit at least 10
fold higher antibody titers in CD-1 mice. The reason for this
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Fig. 4. IgG antibody responses in infant Rhesus macaques (9 per group) vaccinated
with trivalent nOMV vaccines derived from the original or improved vaccine
strains. Geomean ED50 ELISA titers were shown in log scale against vaccine
antigens whose levels were increased in the improved trivalent nOMV vaccine.
Black bars represent titers from the original vaccine strains while gray bars
represent titers from the improved vaccine strains. Error bar represents standard
deviation.
Table 3
Serum bactericidal antibody titers induced by the improved trivalent nOMV vaccines
in infant Rhesus macaques.
Test
strain
Antigens expressed by the
test straina
hSBA geomean titers
Original
trivalent
nOMVs
Improved
trivalent nOMVs
3576 P1.22-1, 4; fHbpv1 8 16
6557 P1.22-1, 14 16 64
M4720 P1.22, 14 <4 <4
190I P1.18, 25b <4 <4
a Only antigens with increased expression levels in the improved trivalent
nOMVs are listed.
b This is the negative control strain, and its porA subtype is listed here even
though it does not match the PorA types contained in the vaccine strains.
4254 L. Zhang et al. / Vaccine 34 (2016) 4250–4256difference is not clear, but one possibility is that the sequence
differences might render fHbpv1 more immunogenic in mice.
Our data suggested that the improved nOMV vaccines consisted
of higher levels of both nPorA and rPorA. As nPorAs at their normal
levels presented in OMV vaccines are able to elicit functional SBA
antibodies, we hypothesized that the increased amount of nPorAs
in our vaccine strains would elicit sufficient anti-nPorA bactericidal
antibodies. Thus, we focused on evaluation of immunogenicity of
rPorAs, P1.7-1, 1 in NB1, P1.22, 14 in NB2 and P1.22-1, 4 in NB3,
that were introduced into these strains by genetic modification
(Table 1, [21]). We showed here that all three improved vaccine
strains derived in the present study resulted in higher levels of
anti-rPorA antibody responses (Fig. 3), consistent with the higher
levels of rPorA surface expression.
nOMVs from the improved strains were then evaluated in IRMs
as a trivalent vaccine. Similarly as in mice, we observed increased
antibody responses to the vaccine antigens with increased expres-
sion levels (Fig. 4). The improved trivalent nOMV vaccine elicited at
about 25 fold higher anti-fHbpv2 IgG antibody titers, about 2 fold
higher anti-fHbpv1 IgG titers, and about 30–100 fold higher anti-
rPorA IgG titers in an ELISA assay. We next evaluated whether
the higher anti-rPorA IgG titers result in higher functional bacteri-
cidal antibody responses in IRMs. The original trivalent nOMV vac-
cine was unable to generate a robust hSBA antibody responseagainst a few test strains, possibly due to either insufficient levels
of antibodies (e.g. anti-fHbpv2 as we showed here) and/or low
level of antigen expression in the test strains [21]. Three of these
strains were chosen to be tested here because they express surface
antigens that are in common with the antigens of increased levels
in our improved nOMV vaccine (Table 3). Strain 3576 expresses
fHbpv1 and PorA subtype P1.22-1, 4 and strain M4720 expresses
PorA subtype P1.22, 14 ([21] and data not shown), and the
improved nOMV vaccine elicited higher antibody response to all
three of these antigens in IRMs. Strain 6557 expresses PorA sub-
type P1.22-1, 14 (data not shown) – this PorA subtype is similar
to P1.22, 14 and the two subtypes might be cross-reactive [33].
Strain 190I was included as a negative control strain, as it does
not have detectable surface expression of fHbp and has a PorA sub-
type that is different from the vaccine strains. As expected, there is
no improvement on the hSBA titer against strain 190I. The
improved nOMV vaccine elicited higher hSBA titers against two
of the test strains (3576 and 6557) as compared to the original
nOMV vaccine, suggesting that antigen specific functional antibody
titers were indeed increased, even though the improvement was
not dramatic as the total IgG titers observed. Increased antibody
levels against fHbp and PorA might both contribute to the increase
hSBA titer against strain 3576. Strain 6557 does not have detect-
able surface expression of fHbp [21], therefore, increased anti-
PorA antibody response is the only driver for the higher hSBA
titers. However, we did not observe an increased hSBA titer against
strain M4720, in contrast with the result obtained for strain 6557,
although both strains express P1.22, 14 or a variant of this subtype.
It is not clear what results in this discrepancy but strain M4720
might be particularly difficult to kill, as it also has good surface
expression of NadA but was unable to be killed with serum gener-
ated from either mice or IRMs and with either the original nOMVs
or the improved nOMVs, even though the vaccines induced signif-
icant anti-NadA antibody response (Fig. 1 and [21]).4. Discussion
The original trivalent nOMV vaccine was designed to induce
broad cross protection against MenB strains [21]. The vaccine has
multiple surface antigens, therefore, it could avoid dependency
on a single antigen or antigen type and potentially induce synergy
of antibodies to different antigens in cases where the surface
expression level of a particular antigen on the N. meningitidis strain
is low [34,35]. Bactericidal titers in immunized rabbits are rela-
tively low, compared to those in immunized mice for both the
homologous MenB strains and the non-serogroup B strains [21–
23]. This difference could result from species differences, suggest-
ing that the titers in humans may be different from those in either
mice or rabbits. Human infants are the primary target population
for a MenB vaccine and a non-human primate model might be
more suitable than a mouse model to predict the antibody
responses to these modified nOMV vaccines in humans [25–27].
Our IRM immunogenicity data showed that the trivalent nOMV
vaccines were immunogenic in IRMs and induced functional anti-
body responses. hSBA titers in IRMs are lower compared to those
in mice [21,22], however, 100% sero-conversion was achieved with
an aluminum adjuvant. This data, together with the data from a
phase I trial of a monovalent nOMV vaccine in healthy adults
[24], suggest that the nOMV vaccine with an appropriate adjuvant
might generate effective hSBA titers in human infants.
In an initial evaluation of the antigen specific antibody
responses, we found that serum antibody response against fHbpv2
was low in immunized IRMs. In both of the recently approved
MenB vaccines, Trumenba and Bexsero, fHbp was primarily
responsible for inducing a broadly protective antibody response.
L. Zhang et al. / Vaccine 34 (2016) 4250–4256 4255Another minor outer membrane antigen, NadA, can elicit protec-
tive bactericidal antibodies and is included in Bexsero. However,
NadA is known to be phase variable and prone to frame-shift
[36–38], and the NadA gene is found in certain clonal complexes
and only present in a small subset of the strains analyzed [39].
Therefore, we sought to increase the fHbp content in the trivalent
nOMVs by further genetic modification of the vaccine strains. By
adding another fHbp gene copy into the porB locus, we have shown
here that nOMVs from the improved vaccine strains possessed
higher fHbp antigen levels and elicited higher fHbp specific anti-
body responses in both mice and IRMs.
We showed that genetic modification can further improve the
immunogenicity and breadth of the nOMV MenB vaccines. The
number of test strains used in this study is limited, given the lim-
ited volume of sera obtained from IRMs. These test strains were not
chosen to represent the current circulating group B strains, but
rather to test the effectiveness of the particular vaccine antigens.
We did not observe increased hSBA titer against strain M4720,
although it has a matched PorA subtype to our vaccine. Similarly,
it was reported that strains with moderate to high NadA and/or
NHBA (neisserial heparin-binding antigen) expression can be resistant
to anti-NadA or anti-NHBA bactericidal antibodies elicited by
4CMenB vaccination [40]. A study involving a larger panel of MenB
strains, as well as other serogroups, may offer a better insight of
the potential of this experimental trivalent nOMV vaccine to
induce a broadly protective antibody response. Previous studies
have demonstrated that killing in the SBA assay can be predicted
by the levels of surface expression of the antigens on the test strain
[41,42]. McNeil et al. reported positive fHbp surface expression on
the majority of the strains tested, using a flow cytometry based
assay [43]. Previous studies showed positive fHbp expression on
about 60–70% of the strains tested using MATS-ELISA [38,42].
The different percentages of strains that have positive fHbp surface
expression might result from different strain collections, and/or
different assays/reagents used. Nonetheless, increased fHbp levels
in the nOMV vaccine would elicit better hSBA against the strains
with positive surface expression of fHbp. For those strains with
low fHbp surface expression, the trivalent nOMV vaccine with mul-
tiple outer membrane antigens would possibly offer broader strain
hSBA coverage through other surface antigens. In addition to the
previous study that showed the trivalent nOMV vaccine’s potential
to elicit SBA against multiple serogroups [22], it was reported
recently that an nOMV vaccine with overexpressed fHbp has
greater potential to confer serogroup-independent protection in
Africa than the licensed 4CMenB vaccine (Bexsero), and inclusion
of fHbpv2 into the nOMV vaccine would further improve strain
coverage for serogroup C strains in certain areas of Africa [44].
Therefore, we speculate that the improved trivalent nOMV vaccine
with higher fHbpv1 and fHbpv2 contents would potentially confer
better hSBA killing against strains from multiple serogroups as
well, compared to the original trivalent nOMV vaccine.
N. meningitidis expresses two distinct porins, PorA and PorB
[45]. Both porins are b-barrel proteins, which associate into trimers
in the bacterial outer membrane through which small hydrophilic
nutrients diffuse into the cell. These porins also appear to have
multiple roles in helping colonization and survival of meningococci
in the blood [46]. Interestingly, we found that fHbp insertion into
the porB locus resulted in higher PorA expression in all three
modified vaccine strains and showed that the modified nOMV
vaccine elicited better hSBA titers against a strain with PorA as
the only hSBA antigen in common with the vaccine strains. It is
not clear why the expression of PorA was increased with porB gene
knockout. As both porins allow nutrient diffusion into cells, one
hypothesis is that during in vitro cell culture following genetic
modification, clones with higher PorA expression levels were
positively selected to compensate for the loss of PorB. In addition,both nPorA and rPorA in the vaccine strains are under the control
of their native promoters [21], therefore, porB gene knockout
might result in up-regulation of both genes via similar signal
transduction pathways.
A genetically optimized OMV approach might have utility for
other bacterial pathogens as well [47]. We show here that the
major surface antigen PorB can be replaced with a heterologous
protein without affecting the fitness of the cells or the ability of
cells to produce outer membrane vesicles. The strong porB pro-
moter resulted in good surface expression of the heterologous anti-
gens, therefore, this approach could be applied to generate other
OMV based vaccines that express different antigens of interest.
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